Skip to main content

Maunsell Farris Maryanne's Form 4 filing

Haemonetics CorpHAE · filed Nov 13, 2026

Accession no.
0000313143-26-000155
Filed
Nov 13, 2026, 4:16 PM ET
Trade date
Nov 11, 2026
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 5 non-derivative transactions and 3 derivative transactions. Open-market sales total $101.1K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Maunsell Farris MaryanneCIK 0001950052Officer (VP, Chief Accounting Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 11, 2026Common StockMOption exerciseAcquired+1,068$89.16+$95,222.887,310Direct
Nov 11, 2026Common StockMOption exerciseAcquired+645$95.73+$61,745.857,955Direct
Nov 11, 2026Common StockMOption exerciseAcquired+433$70.31+$30,444.238,388Direct
Nov 11, 2026Common StockFTax withholdingDisposed−1,724$121.10−$208,776.46,664Direct
Nov 11, 2026Common StockSSaleDisposed−836$120.99F3−$101,147.645,828Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 11, 2026Common StockMOption exerciseDisposed−1,068$0.00$0357Direct
Nov 11, 2026Common StockMOption exerciseDisposed−645$0.00$0646Direct
Nov 11, 2026Common StockMOption exerciseDisposed−433$0.00$01,299Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.87 to $121.10, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)